Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab plus FOLFIRI or FOLFOX as first-line treatment for KRAS wild-type metastatic colorectal cancer
CTR20131098Phase 2Completed
- Sponsor
- Merck KGaA
- Start
- May 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of cetuximab in metastatic colorectal adenocarcinoma (mCRC), sponsored by Merck KGaA. Started May 2014; status: completed.
02
Drugs
cetuximab
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on CTR20131098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20131098.